Whitehawk Therapeutics, Inc. balance sheet WHWK

Annual Quarterly

As of Jun 30, 2026, Whitehawk Therapeutics, Inc. had total assets of $194.0 million and total liabilities of $11.1 million. Total assets were up 7.3% from a year earlier. Stockholders' equity was $182.9 million. Cash and investments were $190.0 million. The current ratio, current assets divided by current liabilities, was 17.38.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Q2 FY2025
Jun 30, 2025
Q1 FY2025
Mar 31, 2025
Q4 FY2024
Dec 31, 2024
Q3 FY2024
Sep 30, 2024
Assets
Cash
85
-41.2%
35
-84.7%
38
+31.0%
38
+24.2%
145
+252.3%
228
+323.1%
29
-54.4%
31
-55.6%
Short-term investments
105
+224.7%
88
+2426.6%
108
+482.4%
125
+288.6%
32
-13.8%
3
-89.9%
19
-59.6%
32
-36.5%
Cash and investments
190
+7.2%
123
-46.7%
146
+208.4%
163
+159.7%
177
+125.5%
231
+161.8%
47
-56.6%
63
-47.5%
Receivables
—
—
0
-100.0%
0
-100.0%
0
-100.0%
0
-100.0%
6
+7.6%
7
+14.4%
Inventory
—
—
0
-100.0%
0
-100.0%
0
-100.0%
0
-100.0%
5
-17.4%
5
+51.3%
Total current assets
192
+7.7%
126
-46.0%
149
+143.1%
165
+113.5%
179
+92.1%
233
+126.8%
61
-50.8%
77
-41.8%
Property and equipment, net
0
-88.9%
0
-92.0%
0
-100.0%
0
-99.9%
0
-99.9%
0
-99.6%
7
+42.6%
6
+66.1%
Total assets
194
+7.3%
127
-45.6%
151
+114.5%
167
+94.9%
181
+77.9%
234
+110.7%
70
-46.9%
86
-38.6%
Liabilities and equity
Accounts payable
1
-66.9%
2
-52.3%
1
-57.5%
2
+18.9%
3
+47.4%
4
+18.2%
2
-63.4%
1
-47.3%
Total current liabilities
11
+26.4%
11
-9.9%
15
-15.0%
10
-37.7%
9
-60.5%
12
-38.2%
17
-35.3%
16
-22.9%
Total liabilities
11
+26.4%
11
-9.9%
15
-18.6%
10
-41.5%
9
-61.6%
12
-40.5%
18
-34.5%
17
-21.6%
Stockholders' equity
183
+6.3%
116
-47.6%
136
+159.7%
157
+128.2%
172
+118.4%
222
+145.1%
52
-50.1%
69
-41.7%
Debt
Lease liabilities
—
—
0
-100.0%
0
-100.0%
0
-100.0%
0
-100.0%
1
-34.3%
1
-30.9%
Total debt
—
—
0
-100.0%
0
-100.0%
0
-100.0%
0
-100.0%
1
-34.3%
1
-30.9%
Net cash
—
—
146
+214.0%
163
+163.6%
177
+128.6%
231
+165.3%
46
-56.9%
62
-47.7%
Ratios
Current ratio
17.38x
11.36x
10.26x
16.76x
20.41x
18.95x
3.59x
4.89x
Debt to equity
—
—
0.00x
0.00x
0.00x
0.00x
0.02x
0.01x
Return on equity
-43.64%
-99.68%
-15.11%
-9.94%
-6.05%
12.45%
-121.37%
-89.57%
Return on assets
-41.15%
-91.02%
-13.66%
-9.35%
-5.76%
11.80%
-90.57%
-71.98%
Book value per share
3.21
2.46
2.89
3.33
3.65
4.74
2.13
2.80
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
WHWK (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Morristown, NJ
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1422142
Former names
Aadi Bioscience, Inc. (until Mar 18, 2025); Aerpio Pharmaceuticals, Inc. (until Aug 23, 2021); ZETA ACQUISITION CORP II (until Mar 13, 2017)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.